Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

Analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Atyr PHARMA in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

Leerink reiterates an Outperform rating and $675 price target on shares of UnitedHealth (UNH). The Wall Street Journal reported that the ...

Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (WBAG:HOLX) from Outperform to Market Perform. There are 1,442 funds or institutions reporting ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As ...